Search
Close this search box.

HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Search
Close this search box.

Special Patient Populations

Management > Special Patient Populations > References

Sections

Sections

References

  1. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2023. Sydney; The Kirby Institute, UNSW: 2023.
  2. 2014 National HIV Testing Policy. v1.0. Available at http://testingportal.ashm.org.au/resources/2014_National_HIV_Testing_Policy_v1.pdf (last accessed 10 August 2016).
  3. Hoyt MJ, Storm DS, Aaron E, Anderson J. Preconception and contraceptive care for women living with HIV. Infect Dis Obstet Gynecol 2012; 2012:604183.
  4. Squires KE, Hodder SL, Feinberg J, et al. Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS 2011; 25:279-85.
  5. Mitchell HS, Stephens E. Contraceptive choice for HIV positive women. Sex Transm Infect 2004; 80:167-73.
  6. Bateson D, McNamee K, O’Connor V. Contraception: an Australian clinical practice handbook. 4th edition. Sydney: Family Planning New South Wales (FPNSW), Family Planning Queensland (FPQ), Family Planning Victoria (FPV); 2016.
  7. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC). US Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use. 2nd edition. MMWR Recomm Rep 2013; 62 (RR05):1-60.
  8. Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstset Gynecol 2012; 2012:890160.
  9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. (Last updated: December 7, 2018; last reviewed: December 7, 2018) Access via: http://aidsinfo.nih.gov/guidelines.
  10. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-80.
  11. Centers for Disease Control and Prevention (CDC). Zidovudine for the prevention of HIV from mother to infant. MMWR Morb Mortal Wkly Rep 1994; 43:285-7.
  12. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
  13. Centers for Disease Control and Prevention. (CDC). Enhanced perinatal surveillance -15 areas, 2005–2008. HIV Surveillance Supplemental Report 2011. 2011;16:2011. Available at: http://www.cdc.gov/hiv/pdf/statistics_2005_2008_HIV_Surveillance_Report_vol_16_no2.pdf (last accessed 3 March 2016).
  14. Whitmore SK, Taylor AW, Espinoza L, et al. Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico. Pediatrics 2012; 129:2010-3691.
  15. Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection – United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006; 55:592-7.
  16. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med 1996; 334:1617-23.
  17. International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15:357-68.
  18. Peters H, Byrne L, De Ruiter A, et al. Duration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance study. BJOG 2016; 123:975-81.
  19. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366:2368-79.
  20. Read JS, Newell MK. Efficacy and safety of caesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005; CD005479.
  21. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 – a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-87.
  22. Briand N, Jasseron C, Sibiude J, et al. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010. Am J Obstet Gynecol 2013; 209:335.e1-335.e12.
  23. Dahlke JD, Mendez-Figueroa H, Rouse DJ, et al. Evidence-based surgery for cesarean delivery: an updated systematic review. Am J Obstet Gynecol 2013; 209:294-306.
  24. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-74.
  25. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-16.
  26. Thomas TK, Masaba R, Borkowf CB, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding – the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 2011; 8:29.
  27. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-80.
  28. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-94.
  29. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
  30. de Ruiter A, Taylor GP, Clayden P, et al, British HIV Association. British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV Med 2014; 15 Suppl 4:1-77. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_487.pdf (last accessed 3 March 2016).
  31. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28:1049-57.
  32. Floridia M, Ravizza M, Pinnetti C, et al Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clin Trials 2010; 11:303-11.
  33. Bardeguez AD, Lindsey JC, Shannon M, et al Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008; 48:408-17.
  34. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 2013; 64:74-8.
  35. Crauwels HM, Baugh B, Ryan R, et al. Total and unbound PK of once daily Darunavir/Ritonavir in HIV-1infected pregnant women. 5th International Workshop on HIV and Women, Seattle, USA; 23-26 February, 2015. Oral abstract O1. Available at: http://regist2.virology-education.com/2015/5thHIVwomen/03_Crauwels.pdf (last accessed 3 March 2016).
  36. Rangopal M, O Osiyemi O, Zorrilla C, et al. Pharmacokinetics of etravirine in HIV infected pregnant women. 5th International Workshop on HIV and Women, Seattle, USA, 23-26 February, 2015. Available at: http://www.croiconference.org/sessions/pharmacokinetics-etravirine-hiv-1–infected-pregnant-women (last accessed 3 March 2016).
  37. Williams PL, Crain MJ, Yildirim C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015; 169:48-55.
  38. Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28 (Suppl 2):S123-131.
  39. Floridia M, Ravizza M, Masuelli G et al. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study. J Antimicrob Chemother 2014; 69:1377-84.
  40. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-15.
  41. Townsend CL, Cortina-Borja M, Peckham CS, Tookey P. Antiretroviral therapy and premature delivery in diagnosed HIV-1 infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-26.
  42. Hitti J, Anderson J, McComsey G, et al. Protease inhibitor-based therapy and glucose intolerance in pregnancy: AIDS Clinical Trials Group A5084 Am J Obstet Gynecol. 2007; 196: e331-337.
  43. Read JS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007; 120:e1547-62.
  44. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012; 160:60-66.
  45. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl J Med 2011; 365:493-505.
  46. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019; 393(10189):2428-2438.
  47. Hankins C. Use of Pre-exposure Prophylaxis (PrEP) in pregnancy for primary prevention of HIV infection in women. 5th International Workshop on HIV and Women. Seattle USA, 23-26 February 2015. Available at: http://regist2.virology-education.com/2015/5thHIVwomen/07_Hankins.pdf (last accessed 3 March 2016).
  48. Abdool Karim Q, Abdool Karim SS, Frolich JA et al. Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science 2010; 329:1168-74.
  49. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR. Achieving safe conception in HIV-sero-discordant couples: the potential role of oral pre-exposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011; 204:e481-488.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top